Ftse Mib
33.089,72
0,00%
DAX
19.261,75
-0,22%
S&P 500
5.998,74
-0,38%
NASDAQ
19.060,48
-0,60%
Bitcoin
95.651,39
-0,34%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CRISPR Therapeutics AG (CRSP) CRISPR Therapeutics AG (CRSP) Notizie

CRSP

CRISPR Therapeutics (CRSP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRSP
DataOraFonteTitoloSimboloCompagnia
14/11/202414:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
13/11/202423:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
07/11/202414:00GlobeNewswire Inc.CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
05/11/202415:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRSPCRISPR Therapeutics AG
05/11/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRSPCRISPR Therapeutics AG
05/11/202415:01GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
05/08/202423:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:CRSPCRISPR Therapeutics AG
05/08/202422:54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRSPCRISPR Therapeutics AG
05/08/202422:01GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
30/05/202422:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
29/05/202414:00GlobeNewswire Inc.CRISPR Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CRSPCRISPR Therapeutics AG
23/05/202414:00GlobeNewswire Inc.CRISPR Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:CRSPCRISPR Therapeutics AG
09/05/202414:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Bank of America Securities Health Care ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
08/05/202422:00GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
08/05/202413:00GlobeNewswire Inc.CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing ApproachNASDAQ:CRSPCRISPR Therapeutics AG
22/04/202422:30GlobeNewswire Inc.CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:CRSPCRISPR Therapeutics AG
03/04/202414:00GlobeNewswire Inc.CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
01/04/202414:00GlobeNewswire Inc.CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:CRSPCRISPR Therapeutics AG
13/03/202413:30GlobeNewswire Inc.CRISPR Therapeutics Proposes New Appointment to the Board of DirectorsNASDAQ:CRSPCRISPR Therapeutics AG
21/02/202413:50Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRSPCRISPR Therapeutics AG
21/02/202413:30GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
15/02/202422:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
15/02/202414:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership SummitNASDAQ:CRSPCRISPR Therapeutics AG
13/02/202414:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CRSPCRISPR Therapeutics AG
13/02/202414:30GlobeNewswire Inc.CRISPR Therapeutics Announces $280 Million Registered Direct OfferingNASDAQ:CRSPCRISPR Therapeutics AG
13/02/202408:30GlobeNewswire Inc.European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)NASDAQ:CRSPCRISPR Therapeutics AG
29/01/202422:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CRSPCRISPR Therapeutics AG
16/01/202422:01GlobeNewswire Inc.CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta ThalassemiaNASDAQ:CRSPCRISPR Therapeutics AG
08/01/202413:00GlobeNewswire Inc.CRISPR Therapeutics Highlights Strategic Priorities and 2024 OutlookNASDAQ:CRSPCRISPR Therapeutics AG
03/01/202414:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRSP

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network